Tirzepatide Dosage Guide: Reconstitution, Injection Volumes, and Escalation Protocol
Research guide to tirzepatide vial reconstitution, dose escalation tables, injection volume calculation, and standard administration protocols for metabolic and obesity research.
Ready to calculate your exact injection volume?
Enter your vial size, concentration, and target dose to get precise volumes instantly.
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown significant effects on weight, blood glucose, and metabolic markers in clinical trials. Research vials require careful reconstitution and a structured dose escalation to minimise GI side effects.
What Vials Typically Come In
Research tirzepatide vials are commonly supplied as:
- 5 mg vials
- 10 mg vials
- 15 mg vials
Clinical formulations (Mounjaro) use prefilled pens at fixed doses (2.5, 5, 7.5, 10, 12.5, 15 mg/0.5 mL). Research vials require manual reconstitution.
How to Reconstitute Tirzepatide
Standard reconstitution for a 5 mg vial:
1. Clean stopper with alcohol swab; allow to dry
2. Add 1 mL bacteriostatic water slowly down the vial wall
3. Swirl gently — do not shake
4. Allow 2–3 minutes for complete dissolution
5. Solution should be clear to slightly yellowish; discard if cloudy or particulate
Concentration examples:
- 5 mg + 1 mL BW → 5000 mcg/mL (5 mg/mL)
- 5 mg + 2 mL BW → 2500 mcg/mL (2.5 mg/mL)
- 10 mg + 2 mL BW → 5000 mcg/mL (5 mg/mL)
Dose Escalation Protocol
Tirzepatide requires a structured escalation to minimise nausea, vomiting, and GI distress:
| Week | Dose | Notes |
|---|---|---|
| Weeks 1–4 | 2.5 mg/week | Starting dose; tolerance phase |
| Weeks 5–8 | 5 mg/week | Step-up if tolerating 2.5 mg |
| Weeks 9–12 | 7.5 mg/week | Step-up if tolerating 5 mg |
| Weeks 13–16 | 10 mg/week | Optional escalation |
| Weeks 17–20 | 12.5 mg/week | Optional escalation |
| Week 21+ | 15 mg/week | Maximum dose in clinical trials |
Do not escalate if GI side effects are significant at the current dose. It is acceptable to stay at any dose that is well-tolerated.
Injection Volume Table
Using a 5 mg/mL reconstituted solution (5 mg in 1 mL BW):
| Target Dose | Volume to Inject |
|---|---|
| 2.5 mg | 0.50 mL (50 units) |
| 5 mg | 1.00 mL (100 units) |
| 7.5 mg | 1.50 mL — split into 2 sites |
| 10 mg | 2.00 mL — split into 2 sites |
Using a 2.5 mg/mL solution (5 mg in 2 mL BW):
| Target Dose | Volume to Inject |
|---|---|
| 2.5 mg | 1.00 mL (100 units) |
| 5 mg | 2.00 mL — split into 2 sites |
| 7.5 mg | 3.00 mL — split into 3 sites |
Use the Dose Calculator for precise injection volumes at any concentration.
Frequency, Timing, and Administration
- Frequency: Once weekly; same day each week
- Injection site: Subcutaneous — abdomen, thigh, or upper arm
- Timing: Any time of day; consistent weekly timing matters more than time of day
- With or without food: No specific food requirement
- Cycle length: 12–52 weeks in major clinical trials
Storage
- Lyophilised vials: 2–8°C (do not freeze)
- After reconstitution: 2–8°C; use within 28 days
- Do not freeze reconstituted solution
Calculate Your Exact Injection Volume
Use our free dose calculator — enter any vial size and target dose to get the precise volume to draw up.
About the Author
KnowYourPeptide Research Team
KnowYourPeptide Research Team
Content produced by the KnowYourPeptide research and editorial team. All articles are written from peer-reviewed primary literature and reviewed for scientific accuracy by credentialed researchers and a board-certified physician before publication.
Meet the full editorial teamMedically Reviewed by Dr. Amanda Reid, MD
This article has been reviewed by Dr. Amanda Reid, MD (Board-Certified Internal Medicine), Know Your Peptide Medical Advisor, for scientific accuracy, safety information, and appropriate clinical context. Learn about our review process.